CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to AGY.L

Fluticasone Propionate, 880 mcg twice daily (after 6FED failure)

Phase 3
Allergy Therapeutics plc (AGY.L)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Eosinophilic Gastrointestinal Disorders (EGIDs)

View Full Landscape
Drug Information

Target Indication

Eosinophilic Gastrointestinal Disorders (EGIDs)

Clinical Trial

NCT02778867

Last updated: 9/15/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.